CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 113 enrolled
Drug / intervention
JCAR017drug
Likely dose
Not stated in record
Key inclusion· 3
  • ✓Histological confirmation of diagnosis at most recent relapse
  • ✓Adequate organ function
  • ✓Adequate vascular access for leukapheresis procedure
Key exclusion· 3
  • ✕Prior CD19-targeted therapy
  • ✕Prior malignancies other than aggressive relapsed/refractory Non-Hodgkin Lymphoma, unless remission ≥2 years (non-invasive malignancies exempt)
  • ✕Progressive vascular tumor invasion, thrombosis, or embolism

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03484702
NCT03484702Phase 2Completed
CompareCT.gov

A Phase 2, Single-arm, Multi-center Trial to Determine the Efficacy and Safety of JCAR017 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or With Other Aggressive B-Cell Malignancies

Celgene·interventional·Posted Apr 2, 2018·Updated Dec 27, 2024

In Brief

A Phase 2 clinical trial evaluating JCAR017 for Lymphoma, Non-Hodgkin. Completed, enrolled 113 participants across 20 sites in 11 countries.

Detailed Summary

The purpose of this study is to evaluate the efficacy and safety of JCAR017 in participants with aggressive B-cell non-Hodgkin lymphoma (B-NHL)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma, Non-Hodgkin
CountriesAustria, Belgium, Finland, France, Germany, Italy, Japan, Netherlands, Spain, Switzerland, United Kingdom
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedApr 2, 2018
Enrollment StartJun 5, 2018
Primary CompletionDec 15, 2023
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 8.3 years ago

Interventions

JCAR017drug

Specified dose on specified days